The 60th annual meeting of the American Society of Hematology (ASH), which will take place in San Diego, CA, December 1-4, 2018, will feature over 30 presentations by Winship Cancer Institute physicians and researchers.
More than 20,000 are expected to attend the annual conference providing the latest advances in hematologic malignancies including leukemia, lymphoma, multiple myeloma, and other blood disorders.
Among the highlights, four Winship researchers will deliver oral presentations on topics in multiple myeloma, and research program leader Lawrence Boise, PhD, will moderate a series of talks on inhibitors in multiple myeloma called "Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Targeting MCL1 and Other Molecular Vulnerabilities in Multiple Myeloma." The four myeloma researchers making oral presentations are part of Boise's lab: Shannon Matulis, PhD, and Brandon Chen will present their findings during the session on inhibitors; research fellow Tyler Moser-Katz will present findings on the role of Syntenin 1 in multiple myeloma cell survival. Ben Barwick, PhD, is lead author of a study on translocations in newly diagnosed myeloma patients. Barwick and Chen received ASH Abstract Achievement Awards.
Christopher R. Flowers, MD, will chair an educational session on follicular lymphoma. The conference will be preceded by the 7th annual Bone Marrow Transplant Winter Workshop led by Edmund K. Waller, MD, PhD, director of Winship's Bone Marrow and Stem Cell Transplant Program.